Threshold Pharmaceuticals Presents Preclinical Results in Two Scientific Presentations at AACR Translational Cancer Medicine Meeting
July 12, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., July 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug,...
Threshold Pharmaceuticals Initiates a Randomized, Controlled, Phase 2 Clinical Trial Evaluating TH-302 in Patients With Advanced Pancreatic Cancer
June 30, 2010 16:36 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 30, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2...
Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating TH-302 in Patients With Advanced Leukemias
June 29, 2010 08:45 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 29, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with...
Threshold Pharmaceuticals Presents Promising Clinical Trial Results Demonstrating Broad Anti-Tumor Activity
June 07, 2010 09:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced results from Phase 1/2 clinical trials in various solid tumors related to its...
Threshold Pharmaceuticals Announces a Presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., June 3, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302....
Threshold Pharmaceuticals Appoints Dr. David R. Parkinson to Board of Directors
May 12, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 12, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced that the Company has appointed Dr. David R. Parkinson to its board of directors....
Threshold Pharmaceuticals Reports First Quarter 2010 Financial and Operational Results
May 07, 2010 08:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 7, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the first quarter ended March 31, 2010.
The net loss for the...
Threshold Announces New Vice President of Corporate Development
May 06, 2010 09:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 6, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced the appointment of Eric Malek as Vice President, Corporate Development. Mr. Malek...
Threshold Pharmaceuticals Presents TH-302 Preclinical Results in Three Scientific Presentations at AACR Annual Meeting
April 20, 2010 08:35 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 20, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today announced multiple preclinical presentations on its clinical stage hypoxia-activated...
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
March 04, 2010 16:00 ET
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 4, 2010 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today reported financial results for the fourth quarter and the year ended December 31,...